Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Cheryl Galt who wrote (490)	6/16/2000 2:17:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 805

Yeah.... they certainly wouldn't be able to sell for some time after any IPO. "In July 1996, CytoTherapeutics, together with certain founding scientists, established Modex Therapeutiques SA ("Modex"), a Swiss biotherapeutics company, to pursue extensions of CytoTherapeutics' broad-based, encapsulated-cell technology for certain applications outside the central nervous system. Modex, headquartered in Lausanne, Switzerland, was formed to integrate technologies developed at three universities in Lausanne (the University of Lausanne, the Centre Hospitalier Universitaire Vaudois, and the Ecole Polytechnique Federale de Lausanne), at the Albert Einstein College of Medicine of Yeshiva University in New York City, and at CytoTherapeutics, to develop products to treat non-CNS diseases such as diabetes, obesity and anemia. In October 1997, the Company completed a series of transactions that resulted in the establishment of Modex as an independent company in which CytoTherapeutics has an equity position of approximately 17%. The pre-existing Cross License Agreement between the Company and Modex, which concerned encapsulated cell technology, was assigned to Neurotech, S.A. in December 1999 as part of the divestiture of the Company's ECT."